Free-to-use UPC cases portal launches

International membership organisation launches platform enabling access to UPC cases and statistics | Tool aims to provide transparency amidst concerns and latest decision requiring legal representation to request access to court documents | Life sciences cases take up two-thirds of UPC cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Unified Patent Court

WATCH: Navigating parallel EPO and UPC revocation actions: strategies, opportunities, and risks

23 May 2026 Managing parallel revocation actions requires a meticulous approach to forum choice and sequencing. This presentation unpacks the lessons learned from the first year of simultaneous EPO and UPC proceedings, offering tactics to leverage opportunities and minimise cross-border risks.

Unified Patent Court

WATCH: Facilitating access to the UPC—economics and navigating the UPC-US patent nexus

15 May 2026 Understanding the economic mechanisms and cross-border interactions of the UPC is crucial for modern patent litigation. This session untangles the complexities of evidence gathering and cost security, highlighting the critical interplay between European proceedings and US patent strategies.

Unified Patent Court

WATCH: Latest developments from the UPC

14 May 2026 Are life sciences cases gaining momentum in the new Unified Patent Court? This session provides a critical update on the UPC's evolving jurisprudence, looking at emerging legal tests and the specific challenges of preliminary injunctions for life sciences products.

More features

Vinson & Elkins grows West Coast patent and trade secrets bench

What’s at stake in Australia’s biggest pharma patent appeal in years?

Will Mounjaro and Zepbound get their first US generic rival?

King & Spalding continues hiring spree from pre-merged Winston

Ashurst Perkins Coie opens its doors following landmark merger

Merck KGaA agrees $11.3bn deal in major life sciences expansion

Pfizer’s US Paxlovid patent fight turns on a single error

Novartis and Eli Lilly sign separate $1.9bn novel drug deals

Free-to-use UPC cases portal launches

More on this story

Editor's picks

Editor's picks

More features